文献速递关节外科骨质疏松与代谢性骨病

阿仑膦酸钠预防全髋关节置换术后股骨距骨丢失的疗效

Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2017-02-27

这项随机研究纳入60例接受初次非骨水泥全髋关节置换的髋骨关节炎患者,随机分为阿仑膦酸钠组(n=20)、阿法骨化醇组(n=18)和对照组(n=22),用双能X线吸收法在术后1周、1年及末次随访(术后至少9年)测量假体周围骨密度。末次随访时所有组股骨距骨密度较术后1周和1年均显著下降(P<.001),阿仑膦酸钠组骨密度显著高于阿法骨化醇组和对照组(P<.05)。结论认为早期使用阿仑膦酸钠可预防股骨距区域骨丢失。

要点

  • 末次随访时股骨距骨密度较基线:阿仑膦酸钠组76%±30%,阿法骨化醇组64%±22%,对照组59%±22%。
  • 所有组股骨距骨密度较术后1周和1年均显著下降(P<.001)。
  • 阿仑膦酸钠组骨密度显著高于阿法骨化醇组和对照组(P<.05)。

核心结论

  • 研究结果表明早期使用阿仑膦酸钠可预防股骨距区域骨丢失。

研究设计与样本

  • 随机研究纳入60例因髋骨关节炎接受初次非骨水泥全髋关节置换的连续患者,随机分为阿仑膦酸钠组(n=20)、阿法骨化醇组(n=18)和对照组(n=22)。
  • 用双能X线吸收法在术后1周、1年和末次随访(术后至少9年)测量假体周围骨密度,骨密度变化以相对术后1周值的平均百分比表示。

主要发现

  • 所有组末次随访时股骨距骨密度较术后1周和术后1年均显著下降(P<.001)。
  • 末次随访时股骨距骨密度为基线值的比例:阿仑膦酸钠组76%±30%,阿法骨化醇组64%±22%,对照组59%±22%。
  • 阿仑膦酸钠组骨密度显著高于阿法骨化醇组和对照组(P<.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone mineral density (BMD) loss around femoral implants, particularly in the proximal femur, is a common outcome after total hip arthroplasty. Previous studies reported the prevention of postsurgical decrease in BMD with the use of osteoporosis drug therapy. This randomized study evaluated the efficacy of alendronate and alfacalcidol for preserving BMD over a long-term follow-up. METHODS: Sixty consecutive patients with hip osteoarthritis who had undergone primary cementless total hip arthroplasty were randomly assigned to an alendronate (n = 20), alfacalcidol (n = 18), or control (n = 22) group. Periprosthetic BMD was measured using dual-energy X-ray absorptiometry at 1 week, 1 year, and the current follow-up (minimum 9 years after surgery). Changes in BMD are reported as mean percentages relative to the values at 1 week (baseline reference). RESULTS: All groups showed a significant decrease in the BMD of the calcar at the current follow-up compared to the values at both 1 week and 1 year postoperatively (P < .001). The BMD values were significantly higher in the alendronate group than in the alfacalcidol and control groups (P < .05). The BMD values at the current follow-up were 76% ± 30% (alendronate group), 64% ± 22% (alfacalcidol group), and 59% ± 22% (control group) of the baseline values. CONCLUSION: Our findings demonstrate the efficacy of early administration of alendronate for the prevention of bone loss in the calcar region.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Yukizawa Y, Inaba Y, Kobayashi N, et al. Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty. J Arthroplasty. 2017. PMID: 28318867. doi:10.1016/j.arth.2017.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。